Literature DB >> 15868332

[Glucocorticoids: importance in the treatment of vasculitis].

P M Aries1, B Hellmich, W L Gross.   

Abstract

Only the modification of natural steroids in the middle of the last century gave insights into the structural requirements for the biological activity of the glucocorticoids (GC). While the delta-4,3-keto-11-beta, 17-alpha,21-trihydroxyl configuration is needed for the GC-activity, an artificial additional double binding in position 1 and 2 lead to a four fold increase of the GC-activity. Of the artificial GC, prednisolone is the most frequently used compound and essential in the therapy of vasculitis today. Dosage, duration and way of application depend on the diagnosis, disease stage, -extend as well as -activity. Considering the use and side-effects of the GC, experiences from cohort-studies of the late 80-ties help at clinical decision making. For giant cell arteritis (GCA) it was shown, that doses of less then 60 mg/day are needed for the induction of remission. Concerning the visual loss in GCA, time of initiating GC-therapy seems more important than the dosage. In the treatment of ANCA-associated vasculitis therapy with GC, later in combination with cyclophosphamide, lead to a significant reduction of mortality. Due to the fact of an increasing survival rate, therapy-related morbidity becomes a more and more important issue. There is a proven correlation between the dosage respectively duration of the GC-therapy and the risk of GC-associated side-effects, especially the incidence of severe infections. This article gives a short review of the present data of the role of GC in the treatment of vasculitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868332     DOI: 10.1007/s00393-005-0717-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  43 in total

1.  Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.

Authors:  G G Hunder; S G Sheps; G L Allen; J W Joyce
Journal:  Ann Intern Med       Date:  1975-05       Impact factor: 25.391

Review 2.  Stopping steroids in polymyalgia rheumatica and giant cell arteritis.

Authors:  V Kyle; B L Hazelman
Journal:  BMJ       Date:  1990-02-10

3.  Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study.

Authors:  G Nesher; A Rubinow; M Sonnenblick
Journal:  Clin Exp Rheumatol       Date:  1997 May-Jun       Impact factor: 4.473

4.  Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.

Authors:  L Guillevin; B Durand-Gasselin; R Cevallos; M Gayraud; F Lhote; P Callard; J Amouroux; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  1999-03

5.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

Authors:  E Reinhold-Keller; N Beuge; U Latza; K de Groot; H Rudert; B Nölle; M Heller; W L Gross
Journal:  Arthritis Rheum       Date:  2000-05

6.  Disease patterns and tissue cytokine profiles in giant cell arteritis.

Authors:  C M Weyand; N Tetzlaff; J Björnsson; A Brack; B Younge; J J Goronzy
Journal:  Arthritis Rheum       Date:  1997-01

7.  Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients.

Authors:  G Nesher; M Sonnenblick; Y Friedlander
Journal:  J Rheumatol       Date:  1994-07       Impact factor: 4.666

8.  Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis.

Authors:  O Rauzy; M Fort; F Nourhashemi; L Alric; H Juchet; M Ecoiffier; M Abbal; D Adoue
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

9.  Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients.

Authors:  L Guillevin; O Fain; F Lhote; B Jarrousse; D Le Thi Huong; A Bussel; A Leon
Journal:  Arthritis Rheum       Date:  1992-02

10.  Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis.

Authors:  F P Ognibene; J H Shelhamer; G S Hoffman; G S Kerr; D Reda; A S Fauci; R Y Leavitt
Journal:  Am J Respir Crit Care Med       Date:  1995-03       Impact factor: 21.405

View more
  1 in total

1.  The Efficacy of Glucocorticoids in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.

Authors:  Pingping Zhou; Jian Zhang; Yanxiu Qi
Journal:  Comput Math Methods Med       Date:  2022-03-18       Impact factor: 2.238

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.